Drug Database
PR

pregabalin (pregabalin, YuHan / YHD 1119 / YHD1119)

✓ Approved

YuHan · CACNA2D1 · Small Molecule

What is pregabalin?

pregabalin is a small molecule developed by YuHan. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namespregabalin, YuHan, YHD 1119, YHD1119
CompanyYuHan
Drug ClassSmall Molecule
Molecular TargetCACNA2D1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

pregabalin acts on 1 molecular target:

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pregabalin is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDiabetic neuropathy✓ Approved
Nervous system disordersPost herpetic neuralgia✓ Approved

Related Research Articles

PubMedCurrent neuropharmacology2026-10-14

From Clinical Manifestations to Neural Mechanisms: A Systematic Review of Neurobehavioral Consequences of Pregabalin Misuse and Abuse.

Guo Wenxiu W, Huang Weisheng W, Weng Ximan X, Li Jiahui J et al.

Pregabalin is a γ-aminobutyric acid (GABA) analog. It is prescribed for neuropathic pain, fibromyalgia, anxiety disorders, and seizures. Pregabalin misuse and abuse have increased rapidly worldwide in recent years, raising public concerns owing to its addictive potential and associated neurotoxicity. To systematically characterize the neurobehavioral effects of pregabalin misuse and abuse, recent research was synthesized, and the relevant literature was reviewed to identify key findings, explore limitations, and outline future directions. This systematic review followed the PRISMA guidelines. PubMed, Embase, Web of Science, CNKI, and Wanfang were searched for literature covering case series, cross-sectional, prospective, and retrospective studies, and animal experiments. The study's focus was to synthesize evidence of the neurobehavioral consequences of pregabalin misuse and abuse, and explore the association between clinical symptoms and neurobiological mechanisms. A total of 23 studies met the inclusion criteria. Acute overdose consistently produced neuroinhibitory symptoms and reward-seeking behaviors. Repeated or chronic exposure was associated with dose-dependent cognitive impairment, psychiatric comorbidity, addiction, and withdrawal syndrome. Preclinical studies revealed dopaminergic dysregulation, oxidative stress, and neuroadaptive remodeling. Human evidence consistently links acute overdose to neuroinhibitory symptoms and reward-seeking behaviors, with severity correlating with dose. Preclinical studies provide a plausible mechanistic hypothesis: acute pregabalin exposure may activate mesolimbic dopamine signaling while chronic high-dose exposure is associated with monoamine disruption, oxidative stress, inflammatory activation, and receptor remodeling in animal models. Direct translation of these findings to human pathophysiology warrants further investigation. Pregabalin misuse and abuse is associated with serious neurobehavioral risks, including acute neurotoxicity, chronic cognitive and psychiatric impairment, and addiction risk. However, the evidence base remains limited, and causal inference is constrained by the predominance of observational human studies and the preliminary nature of animal mechanistic data. Further research should refine risk stratification and inform public health strategies for early identification and intervention.

PubMedPain medicine case reports2026-10-14

Peripheral Nerve Stimulator Implant for Superior Cluneal Neuralgia in Patients with Peripheral Neuropathy: A Case Series.

Purvez Akhtar A, Mir Ana A, Mir Sama S

Superior cluneal neuralgia is a recognized but often underdiagnosed cause of chronic axial low back and leg pain. Peripheral nerve stimulation (PNS) has shown promise in treating neuropathic pain disorders. We report 2 patients-one with diabetic peripheral neuropathy and another with idiopathic neuropathy-who underwent PNS implantation for superior cluneal neuralgia. Both patients were on high doses of neuropathic pain medications (gabapentin or pregabalin), and one was also taking duloxetine. Following implantation, both experienced marked pain relief, allowing reduction and eventual discontinuation of these medications. The Freedom® Peripheral Nerve Stimulator System (Curonix LLC) showed reductions in pain, alongside a favorable safety profile. These results support the clinical utility of high-frequency electromagnetic coupling-based PNS as a minimally invasive and clinically valuable treatment option for chronic neuropathic pain and highlight its potential to reduce the intake of pharmacologic agents.

PubMedJournal of opioid management2026-10-14

Comparison of long-term outcomes between opioid-free and opioid-based anesthesia in head and neck cancer surgeries: A pilot study.

Kataria Nitin N, Chilkoti Geetanjali T GT, Jain Swati S, Mohta Medha M et al.

Background, aim, and objective: Literature is replete with studies evaluating opioid-sparing strategies in head and neck cancer (HNC) surgeries; however, no study has attempted opioid-free anesthesia (OFA). Various long-term outcomes have not been evaluated in any cancer surgeries. This study aimed to compare OFA with standard opioid-based anesthe-sia (OBA) in HNC surgeries. The primary objective was the incidence of chronic post-surgical pain (CPSP), and the sec-ondary objective included Numeric Rating Scale (NRS)-Pain scores, Neuropathic Pain Symptom Inventory (NPSI), Douleur Neuropathique 4 (DN-4), Pain Detect Questionnaire (PDQ), and Short Form-12 (SF-12) scores. Following Instituitional Ethics Committee approval and prospective Clinical Trials Registry-India registration, the study included patients with American Society of Anesthesiologists Physical Status II or III, aged 20-65 years, who were undergoing HNC surgeries. Patients were excluded if they had a history of post-operative nausea, chronic pain, opioid use, local anesthetic allergies, coagulopathies, or cognitive dysfunction. Group OFA received oral pregabalin and dexmedetomidine and ketamine intravenous (IV) infusions perioperatively. Group OBA received standard OBA with IV morphine boluses. The various aforementioned secondary objectives were recorded at the fourth, sixth, eighth, and 12th weeks. Fifty patients, with 25 in each group, were included. The demographic profiles were comparable between the groups. NRS-Pain (Rest) was comparable; however, mean NRS (Cough) and NRS (Swallow) scores were lower in the OF group at the sixth week; however, this difference was not significant. No patients developed CPSP in any group. No sig-nificant differences were recorded in PDQ, NPSI, DN-4, Activity Assessment Scale, and SF-12 scores. Similarly, me-chanical ventilation duration, intensive care unit stay, total hospital stays, and mortality rates were comparable. We did not observe any association between CPSP and OFA in HNC surgeries. Additionally, pain intensity, neuropathic pain component, quality of recovery, and quality of life were comparable.

PubMedFrontiers in neurology2026-10-13

Association of platelet-rich plasma combined with dorsal root ganglion-targeted pulsed radiofrequency with outcomes in subacute thoracic herpes zoster neuralgia: a retrospective cohort study.

Ye Xiaolong X, Hu Xin X, Zhou Zenghua Z, Xu Shengrong S et al.

Subacute herpes zoster neuralgia is a clinically important transitional stage before pain becomes fully established as persistent postherpetic neuralgia. In this single-center retrospective cohort study, patients with subacute thoracic herpes zoster neuralgia treated between January 2024 and December 2025 were identified from routine clinical records. Patients were classified according to the treatment received as PRP + PRF or PRF alone. The primary outcome was the Numerical Rating Scale (NRS) score at 3 months after treatment. Repeated NRS and Pittsburgh Sleep Quality Index (PSQI) measurements were analyzed longitudinally. Secondary outcomes included pregabalin requirement and persistent clinically meaningful zoster-related pain, defined as NRS > 3 at the 3-month post-treatment follow-up. Seventy patients were analyzed, including 36 in the PRP + PRF group and 34 in the PRF group. At 3 months, the observed mean NRS score was lower in the PRP + PRF group than in the PRF group (1.39 ± 1.44 vs. 2.56 ± 1.02). In the prespecified ANCOVA adjusted for baseline NRS, PRP + PRF was associated with a lower 3-month NRS score than PRF alone (adjusted mean difference, -1.13; 95% confidence interval [CI], -1.71 to -0.54; p < 0.001). The association remained directionally consistent in additional multivariable and change-score sensitivity analyses. Significant group-by-time interactions were observed for NRS and PSQI, with lower NRS and PSQI scores in the PRP + PRF group from 1 week through 3 months. Pregabalin requirement at 3 months was lower in the PRP + PRF group (p = 0.001). Persistent clinically meaningful zoster-related pain at 3 months occurred in 4 of 36 patients (11.1%) in the PRP + PRF group and 7 of 34 patients (20.6%) in the PRF group (p = 0.336). In this retrospective cohort, PRP combined with DRG-targeted PRF was associated with faster early improvement in pain and sleep and with lower post-treatment pregabalin use than PRF alone. Further prospective studies are needed to confirm these findings and determine whether this approach influences progression to persistent pain and PHN.

PubMedThe Journal of pharmacology and experimental therapeutics2026-10-13

Comparison of monosodium iodoacetate, medial meniscal transection, and partial medial meniscectomy in vivo rat models of osteoarthritis from the pain and industrial perspective.

Lehtinen Paula P, Ailanen Liisa L, Kela Johanna J, Virtanen Sami S et al.

Osteoarthritis (OA) is a major global health burden marked by progressive cartilage degeneration and chronic pain with intertwined inflammatory and neuropathic mechanisms. This study compared three rat OA models, monosodium iodoacetate (MIA), medial meniscal transection (MMT), and partial medial meniscectomy (MNX), to assess their translational value, suitability for pharmaceutical research, and identify the most robust and reproducible model for preclinical OA pain research. OA was induced in male Wistar (MIA) or Sprague Dawley (MMT, MNX) rats, and pain progression was evaluated by testing mechanical sensitivity and dynamic weight-bearing. A single oral dose of pregabalin (30 mg/kg) was used for pharmacological validation. The MIA model produced a rapid, robust pain phenotype, with pronounced mechanical hypersensitivity and consistent weight-bearing deficits by day 21. Surgical models progressed more slowly and variably: hypersensitivity emerged by day 21 in MNX rats and by day 49 in MMT rats. Neither surgical model generated stable dynamic weight-bearing deficits, indicating limited sensitivity of current gait-analysis methods for detecting their subtler impairments. Pregabalin reduced mechanical hypersensitivity across all 3 models, confirming their pharmacological validity and utility for analgesic screening. Overall, the MIA model remains the most efficient and reliable for industrial research due to its strong behavioral window, whereas the MNX model offers greater translational relevance if paired with more sensitive and objective behavioral measures. SIGNIFICANCE STATEMENT: By systematically comparing chemical and surgical rat models of osteoarthritis, this study clarifies their strengths and limitations for modeling chronic pain. The results demonstrate that, although the monosodium iodoacetate model delivers robust, reproducible behavioral outcomes, surgical models more accurately reflect disease progression but lack sensitive behavioral readouts. This work informs translational model selection and underscores the need for more objective pain assessment tools.

PubMedPain research & management2026-10-12

An Exploratory Retrospective Comparison of Crisugabalin and Pregabalin Among 12-Week Treatment Completers With Postherpetic Neuralgia.

Shang Rui-Tao RT, Chen Qian-Qian QQ, Zhang Jia-Yi JY, Lou You-Pan YP et al.

Pregabalin (PGB) is commonly used for postherpetic neuralgia (PHN), but its clinical effectiveness may be limited by insufficient pain relief or adverse events (AEs). Crisugabalin (CGB) is a novel α2δ-1 ligand that has demonstrated efficacy in randomized placebo-controlled trials. However, comparative real-world evidence for CGB and PGB remains limited. This single-center retrospective cohort study included patients with PHN who completed at least 12 weeks of CGB or PGB monotherapy between January and June 2025. In October 2025, a single structured telephone interview was conducted to retrospectively assess patients' recalled status at treatment initiation (T0) and at Weeks 1, 4, and 12. Outcomes included the Numerical Rating Scale (NRS), Pittsburgh Sleep Quality Index (PSQI), and the physical and mental component summary scores of the 36-Item Short Form Health Survey (SF-36). Linear mixed effects models (LMMs) were designated as the primary analyses and adjusted for age, sex, pain location, pre-enrollment pain duration, hypertension, and diabetes. Repeated measures analysis of variance and the LMM analysis based on inverse probability weighting of propensity scores were performed as sensitivity analysis. Safety outcomes were descriptively assessed among treatment completers. A total of 113 patients were included, including 56 in the CGB group and 57 in the PGB group. In the adjusted LMMs, significant treatment-by-time interactions were observed for NRS scores (p < 0.001), PSQI scores (p < 0.001), and SF-36 mental component summary scores (p = 0.003), the extent to which these three scores of the CGB group improved over time may be higher than that of the PGB group. The treatment-by-time interactions were not statistically significant for SF-36 physical component summary scores (p = 0.377). Sensitivity analyses using repeated measures analysis of variance produced concordant findings for NRS, PSQI, and SF-36 mental component scores but not for SF-36 physical component scores. At least one AE was reported by 11 of 56 patients in the CGB group and 18 of 57 patients in the PGB group, but there was no overall significant difference in AEs (p = 0.196). Among patients who completed 12 weeks of treatment, the CGB group was associated with statistical differences to some extent in NRS, PSQI, and SF-36 mental component scores than PGB group, and these degree of improvement over time may be more pronounced. Due to the substantial bias in retrospective studies and the relatively small sample size, these findings should be interpreted as exploratory, merely have reference value, and require more confirmation in prospective controlled studies in the future.

+5374 more articles available with a free account

Sign up free to view all articles →

Ask about pregabalin